Follow
Satyaprakash Nayak
Title
Cited by
Cited by
Year
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
WJ Sandborn, SD Lee, D Tarabar, E Louis, M Klopocka, J Klaus, ...
Gut 67 (10), 1824-1835, 2018
1102018
Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems
R Tasseff, S Nayak, S Salim, P Kaushik, N Rizvi, JD Varner
PLoS One 5 (1), e8864, 2010
422010
A test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials
S Nayak, S Salim, D Luan, M Zai, JD Varner
PLoS One 3 (4), e2016, 2008
322008
Modelling and analysis of an ensemble of eukaryotic translation initiation models
S Nayak, JK Siddiqui, JD Varner
IET systems biology 5 (1), 2-14, 2011
302011
Modeling and analysis of retinoic acid induced differentiation of uncommitted precursor cells
R Tasseff, S Nayak, SO Song, A Yen, JD Varner
Integrative biology 3 (5), 578-591, 2011
292011
Anti-MAdCAM antibody increases ß7+ T cells and CCR9 gene expression in the peripheral blood of patients with Crohn’s disease
M Hassan-Zahraee, A Banerjee, JB Cheng, W Zhang, A Ahmad, K Page, ...
Journal of Crohn's and Colitis 12 (1), 77-86, 2018
282018
Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML–RARα negative human myeloblastic …
S Nayak, M Shen, RP Bunaciu, SE Bloom, JD Varner, A Yen
Leukemia & lymphoma 51 (9), 1-14, 2010
262010
Computational modeling and analysis of insulin induced eukaryotic translation initiation
J Lequieu, A Chakrabarti, S Nayak, JD Varner
PLoS computational biology 7 (11), e1002263, 2011
252011
Using a systems pharmacology model of the blood coagulation network to predict the effects of various therapies on biomarkers
S Nayak, D Lee, S Patel‐Hett, DD Pittman, SW Martin, AC Heatherington, ...
CPT: pharmacometrics & systems pharmacology 4 (7), 396-405, 2015
242015
Getting innovative therapies faster to patients at the right dose: impact of quantitative pharmacology towards first registration and expanding therapeutic use
S Nayak, O Sander, N Al‐Huniti, D de Alwis, A Chain, M Chenel, ...
Clinical Pharmacology & Therapeutics 103 (3), 378-383, 2018
222018
A dynamic quantitative systems pharmacology model of inflammatory bowel disease: Part 1–model framework
KV Rogers, SW Martin, I Bhattacharya, RSP Singh, S Nayak
Clinical and Translational Science 14 (1), 239-248, 2021
162021
Evaluating the role of Janus kinase pathways in platelet homeostasis using a systems modeling approach
S Koride, S Nayak, C Banfield, MC Peterson
CPT: Pharmacometrics & Systems Pharmacology 8 (7), 478-488, 2019
162019
Long-term safety and efficacy of the anti-mucosal addressin cell adhesion molecule-1 monoclonal antibody ontamalimab (SHP647) for the treatment of Crohn’s disease: the OPERA II …
GR D’Haens, W Reinisch, SD Lee, D Tarabar, E Louis, M Kłopocka, ...
Inflammatory Bowel Diseases 28 (7), 1034-1044, 2022
102022
Transforming translation through quantitative pharmacology for high‐impact decision making in drug discovery and development
N Gupta, D Bottino, USH Simonsson, CJ Musante, T Bueters, TR Rieger, ...
Clinical Pharmacology & Therapeutics 107 (6), 1285-1289, 2020
92020
A dynamic quantitative systems pharmacology model of inflammatory bowel disease: Part 2–application to current therapies in Crohn’s disease
KV Rogers, SW Martin, I Bhattacharya, RSP Singh, S Nayak
Clinical and Translational Science 14 (1), 249-259, 2021
72021
Know your variability: challenges in mechanistic modeling of inflammatory response in inflammatory bowel disease (IBD)
KV Rogers, I Bhattacharya, SW Martin, S Nayak
Clinical and Translational Science 11 (1), 4, 2018
72018
A quantitative systems pharmacology model of blood coagulation network describes in vivo biomarker changes in non‐bleeding subjects
D Lee, S Nayak, SW Martin, AC Heatherington, P Vicini, F Hua
Journal of Thrombosis and Haemostasis 14 (12), 2430-2445, 2016
72016
Modeling and simulation of the modified Rankin Scale and National Institutes of Health Stroke Scale neurological endpoints in intracerebral hemorrhage
R Schoemaker, S Nayak, LO Harnisch, MO Karlsson, ...
Journal of Pharmacokinetics and Pharmacodynamics 46 (5), 473-484, 2019
32019
A review of quantitative modeling of B cell responses to antigenic challenge
TP Hickling, X Chen, P Vicini, S Nayak
Journal of Pharmacokinetics and Pharmacodynamics 41 (5), 445 - 459, 2014
32014
Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective
R Zhu, B Vora, S Menon, I Younis, G Dwivedi, Z Meng, A Datta‐Mannan, ...
Clinical Pharmacology & Therapeutics 114 (4), 751-767, 2023
22023
The system can't perform the operation now. Try again later.
Articles 1–20